Tag Archive for: Roche

AC Immune at the EPFL Innovation Park © AC Immune

Genentech, Roche’s US subsidiary, is ending its decades-long collaboration with AC Immune SA after disappointing study results. It has handed the global rights to Crenezumab and Semorinemab back to the Lausanne-based biotech.

EM picture of A. baumannii. © Vader1941 - wikipedia.org

Hoffmann-La Roche AG has published details on the mechanism of action of its Phase I antibiotic Zosurabalpin (RG6006) that kills the carbapenem-resistant bug Acinetobacter baumannii.
.

TLA1 mode of action. In fibrosis, the compound's binding to its receptor induces TGF-beta and IL6 release. © Prometheus Biosciences/MSD

Analysts describe as sporting the €7.1bn for Roche AG’s acquisition of Roivant subsidiary Telavant Holdings.

Alnylam CEO Yvonne-Greenstreet. © Alnylam Pharmaceuticals.jpg

siRNA specialist Alnylam Pharmaceuticals Roche has received US$310m upfront from Swiss Roche AG for the ex-US commercialisation rights of zilebesiran, an new antihypertensive.
T

Roche tower I. © Norbert Aepli, Switzerland

Roche’s bruton’s tyrosine kinas blocker fenebrutinib has met all endpoints in proof-of-concept study with patients suffering from relapsing-remitting multiple sclerosis.

T-Cell-Dendritic-Cell interaction. © Hookipa

HOOKIPA has received a US$10m milestone under its 2022 agreement with Roche to develop an arenaviral immunotherapy for KRAS-mutated cancers.

PD-L1 blocks PD-L1 and B7.1 receptors on T cells thus triggering inactivation of cytotoxic T cells. © Genbentech Inc

Roche AG’s US subsidiary Genentech Inc has withdrawn its checkpoint inhibitor atezolizumab from the market after disappointing results in bladder cancer.

©Roche

Schwan follows Franz, Schinecker follows Schwan.